DBS for treatment-resistant depression has not been approved by the U.S Food and Drug Administration (FDA) and the safety and ... September 2022, Abbott received Breakthrough Device designation ...

Abbott is studying deep brain stimulation (DBS) as a potential treatment for depression, taking the technology in a direction that could advance other mental health therapies. Abbott received FDA ...

DBS for treatment-resistant depression has not been approved by the U.S Food and Drug Administration (FDA) and the safety and effectiveness ... In September 2022, Abbott received Breakthrough Device ...

With PFA becoming physicians’ preferred ablation method for treating AFib, Abbott is pushing to catch up with rival systems ...

Abbott (NYSE: ABT) announced today that it launched a next-generation delivery system for its neuromodulation business.

Abbott’s pulse field ablation system competes with products from Medtronic and Boston Scientific, which also have large ...

Abbott said its Volt system is designed to improve upon what it sees as the limitations of first-generation PFA devices. Abbott has trailed medtech competitors in bringing a PFA device to market ...

Abbott took "a deliberately very different development path ... for the waveform" behind its Volt PFA system, said Dr.

The initiative aims to reduce treatment costs and reliance on imported medical devices. The 1.5 Tesla MRI system has been developed by SAMEER, an autonomous R&D institution under the Ministry of ...

BD, Medtronic and Abbott were among the top 10 device companies with the highest number of late reports to the FDA, the study found.

Abbott received a breakthrough device designation from the US Food and Drug Administration (FDA) to investigate the use of its DBS system for TRD in 2022. According to Dr Brian Kopell, director of ...

The worldwide use of both magnetic resonance imaging (MRI) and pacing devices has vastly increased ... systems have been specifically designed for safe use in the MRI environment and the first ...